Does Obesity Reduce Drug Efficacy in Breast Cancer? Does Obesity Reduce Drug Efficacy in Breast Cancer?
Poor survival outcomes occurred among overweight patients treated with docetaxel-based adjuvant chemotherapy compared with peers given a non-taxane-based regimen.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 11, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Popular chemotherapy drug may be less effective in overweight and obese women
(KU Leuven) Breast cancer patients who are overweight or obese might benefit less from treatment with docetaxel, a common chemotherapy drug, than lean patients, a new study finds. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 2, 2020 Category: International Medicine & Public Health Source Type: news

FDA approves Roche ’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer
             Basel, 29 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Phesgo ™, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection in combination with intravenous (IV) chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer. This is the first time that Roche has combined two monoclonal antibodies that can be administered by a single SC i...
Source: Roche Media News - June 29, 2020 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer
             Basel, 29 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Phesgo ™, a fixed-dose combination of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subcutaneous (SC; under the skin) injection in combination with intravenous (IV) chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer. This is the first time that Roche has combined two monoclonal antibodies that can be administered by a single SC i...
Source: Roche Investor Update - June 29, 2020 Category: Pharmaceuticals Source Type: news

Phase II Trial Finds LuPSMA May be Effective for Men with mCRPC
The results, presented at the 2020 ASCO Virtual Scientific Program, found that in men with metastatic castration resistant prostate cancer who were previously treated with docetaxel, 177Lu-PSMA-617 (LuPSMA) was more active than cabazitaxel. (Source: CancerNetwork)
Source: CancerNetwork - May 29, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Carboplatin-Pemetrexed Effective for Elderly Patients With Non-small Cell Lung Cancer Carboplatin-Pemetrexed Effective for Elderly Patients With Non-small Cell Lung Cancer
Carboplatin plus pemetrexed followed by maintenance pemetrexed is an effective alternative to docetaxel monotherapy for elderly patients with advanced nonsquamous non-small cell lung cancer (NSCLC), researchers in Japan report.Reuters Health Information (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 25, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA accepts Roche ’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer
Basel, 25 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for the fixed-dose combination (FDC) of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subc utaneous (SC) injection in combination with intravenous (IV) chemotherapy, for the treatment of eligible patients with HER2-positive breast cancer. The BLA for the FDC is based on results from the phase III FeDeriCa study, which demonstrated non-inferior levels of Perjeta in the blood (phar...
Source: Roche Investor Update - February 25, 2020 Category: Pharmaceuticals Source Type: news

FDA accepts Roche ’s Biologics License Application for fixed-dose subcutaneous combination of Perjeta and Herceptin for HER2-positive breast cancer
Basel, 25 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for the fixed-dose combination (FDC) of Perjeta® (pertuzumab) and Herceptin® (trastuzumab) with hyaluronidase, administered by subc utaneous (SC) injection in combination with intravenous (IV) chemotherapy, for the treatment of eligible patients with HER2-positive breast cancer. The BLA for the FDC is based on results from the phase III FeDeriCa study, which demonstrated non-inferior levels of Perjeta in the blood (phar...
Source: Roche Media News - February 25, 2020 Category: Pharmaceuticals Source Type: news

Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GU
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet...
Source: Johnson and Johnson - February 3, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Armas Pharmaceuticals Adds Four Generic Injectables As First Launches of 2020
MANALAPAN, N.J., Jan. 20, 2020 -- (Healthcare Sales & Marketing Network) -- Armas Pharmaceuticals Inc. (Armas), has begun the new year with launches of four generic injectables: Caffeine Citrate, Docetaxel, Gemcitabine and Verapamil HCI. These products ar... Biopharmaceuticals, Generics, Product Launch Armas Pharmaceuticals, CAFCIT, Taxotere, Gemzar, Verapamil (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 20, 2020 Category: Pharmaceuticals Source Type: news

Docetaxel cost-saving alternative to abiraterone in prostate cancer
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - January 1, 2020 Category: Drugs & Pharmacology Source Type: news

Company-led drug alert – docetaxel injection 80mg /8ml
Pfizer UK Limited is recalling certain batches of docetaxel injection 80mg /8ml. (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - October 22, 2019 Category: Drugs & Pharmacology Source Type: news

Nivolumab Still Has Edge on Chemo After 4 Years in Advanced NSCLC Nivolumab Still Has Edge on Chemo After 4 Years in Advanced NSCLC
Patients with advanced non-small-cell lung cancer (NSCLC) who are treated with the anti-PD-1 antibody nivolumab continue to have better survival than those given docetaxel after four years, according to pooled data from four CheckMate trials.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - September 4, 2019 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Independent Advisory Group (Tayside Breast Cancer) report
This report makes 19 recommendations for medicines governance following allegations of under-dosing of two oncology medicines included in the chemotherapy regimen known as the FEC-T (fluorouracil, epirubicin, cyclophosphamide and docetaxel) (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - August 28, 2019 Category: Consumer Health News Source Type: news

docetaxel (Taxotere, Docefrez)
Title: docetaxel (Taxotere, Docefrez)Category: MedicationsCreated: 3/12/2000 12:00:00 AMLast Editorial Review: 8/22/2019 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - August 22, 2019 Category: Cancer & Oncology Source Type: news

Researchers confirm the validity of xenographic models for studies of methylation
(IDIBELL-Bellvitge Biomedical Research Institute) Researchers at the Bellvitge Biomedical Research Institute (IDIBELL), published today in Molecular Cancer Research a study where they identify methylation patterns associated with different subtypes of breast cancer, and a subclassification of the group of " triple negatives " , a breast cancer type typically associated with poor prognosis. In addition, researchers identified changes in DNA methylation associated with the response to docetaxel, a common therapy. The research was led by Dr. Eva Gonz á lez-Su á rez, head of the IDIBELL Transformation a...
Source: EurekAlert! - Cancer - July 18, 2019 Category: Cancer & Oncology Source Type: news

Company led recall – Docetaxel Injection 160mg/16ml and 20mg/2ml
Pfizer UK Limited isrecalling batches as routine stability testing has identified that levels of a known impurity, 10-oxo-docetaxel, may exceed the acceptable level at the end of shelf-life. Further (Source: Royal Pharmaceutical Society News)
Source: Royal Pharmaceutical Society News - June 24, 2019 Category: Drugs & Pharmacology Source Type: news

Can T-DM1 Match Chemotherapy Plus Dual Blockade in HER2+ Breast Cancer?
A phase II trial tested docetaxel, trastuzumab, and pertuzumab vs T-DM1 for the neoadjuvant treatment of HER2+ breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 14, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Dr. Gadgeel on Docetaxel Plus Trametinib in KRAS-Mutated Recurrent NSCLC
In this video, Shirish M. Gadgeel, MD, of  Rogel Cancer Center, University of Michigan, discusses combo docetaxel/trametinib in G12C or non-G12C KRAS mutation-positive, recurrent NSCLC. (Source: CancerNetwork)
Source: CancerNetwork - June 10, 2019 Category: Cancer & Oncology Authors: Shirish M. Gadgeel, MD Source Type: news

Can Metformin Improve Outcomes When Added to Chemotherapy in Prostate Cancer?
The TAXOMET trial tested the addition of metformin to docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 6, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Better Longer-Term Survival in NSCLC After Nivolumab Response Better Longer-Term Survival in NSCLC After Nivolumab Response
Previously treated patients with advanced NSCLC who responded to nivolumab had long-term survival that was notably higher than patients who received docetaxel.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 8, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Docetaxel Chemo Ups Survival in High - Risk Localized Prostate Cancer
Findings based on addition of docetaxel chemotherapy to androgen suppression, radiotherapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 29, 2019 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Urology, Journal, Source Type: news

Docetaxel Chemo Ups Survival in High-Risk Localized Prostate Cancer
THURSDAY, March 28, 2019 -- Adding docetaxel-based chemotherapy (CT) to standard treatment for high-risk nonmetastatic prostate cancer improves survival, according to a study published online March 12 in the Journal of Clinical Oncology. Seth A.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 28, 2019 Category: Pharmaceuticals Source Type: news

Chemo for Early-Stage Prostate Cancer? RTOG 0521 Says Maybe Chemo for Early-Stage Prostate Cancer? RTOG 0521 Says Maybe
In major clinical trial, docetaxel, which is typically used in metastatic disease, improved outcomes in high-risk, early-stage disease. However, the survival results fell short of the trial target.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 18, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Adding docetaxel-based chemotherapy to standard treatment for high-risk prostate cancer
(NRG Oncology) Researchers theorized that adding adjuvant docetaxel, a cytotoxic chemotherapy drug, to the standard of care RT and long-term AS treatment could potentially improve overall survival and clinical outcomes for men with localized, high-risk prostate cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 12, 2019 Category: Cancer & Oncology Source Type: news

Adding Docetaxel to ADT for High-Risk Nonmetastatic Prostate Cancer: Does It Help?
Researchers tested the combination of docetaxel and ADT in a phase III randomized trial of patients with high-risk nonmetastatic prostate cancer. (Source: CancerNetwork)
Source: CancerNetwork - March 8, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

No Benefit With Adjuvant Docetaxel in Nonmetastatic Prostate Cancer (CME/CE)
(MedPage Today) -- ADT with or without docetaxel yielded similar PFS at 10 years in androgen-dependent disease (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 5, 2019 Category: Hematology Source Type: news

Adjuvant Docetaxel No Help in High-Risk Prostate Cancer
(MedPage Today) -- Similar rates of progression at 10 years in androgen-dependent disease (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 31, 2019 Category: Hematology Source Type: news

Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel
This review of data from 9 RCTs (n=8,820) found a longer median overall survival for black men vs white men (21.0 vs 21.2 months, multivariable HR 0.81, 95% CI 0.72-0.91). The mechanism for this difference was unknown. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 9, 2019 Category: Consumer Health News Source Type: news

VARGADO data
Vargatef ® plus docetaxel could be an option after failure of immunotherapy in lung cancerResults from a real-world study1  support a recent update to the ESMO guidelines2 recommending nintedanib (Vargatef®) plus docetaxel following first-line chemotherapy (+/- immunotherapy) in advanced NSCLC of adenocarcinoma histology (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 13, 2018 Category: Research Source Type: news

Taxotere (Docetaxel for Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 19, 2018 Category: Drugs & Pharmacology Source Type: news

What Role Will Avelumab Play in Lung Cancer?
Avelumab did not improve overall survival compared with docetaxel in patients with PD-L1 –positive non–small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - October 17, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Nivolumab Is China ’s First Approved Immuno-Oncology Drug
In CheckMate -078, nivolumab yielded superior OS compared with docetaxel in previously treated NSCLC, regardless of PD-L1 expression and tumor histology. (Source: CancerNetwork)
Source: CancerNetwork - June 27, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Adjuvant Docetaxel Fails in Higher-Risk Prostate Cancer
In SPCG-13, adjuvant docetaxel without prednisone did not impact biochemical DFS in intermediate- or high-risk disease treated with radical RT with ADT. (Source: CancerNetwork)
Source: CancerNetwork - June 13, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

$200K Saved With First-Line Docetaxel for Prostate Cancer $200K Saved With First-Line Docetaxel for Prostate Cancer
For the first time, there is a cost-effectiveness study on two systemic drugs used in the treatment of newly diagnosed metastatic prostate cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 12, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Adjuvant Docetaxel Fails in Higher-Risk Prostate Ca
In SPCG-13, adjuvant docetaxel without prednisone did not impact biochemical DFS in intermediate- or high-risk disease treated with radical RT with ADT. (Source: CancerNetwork)
Source: CancerNetwork - June 11, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

No DFS Benefit: Adjuvant Docetaxel in Higher-Risk Prostate Ca
In SPCG-13, adjuvant docetaxel without prednisone did not impact biochemical DFS in intermediate- or high-risk disease treated with radical RT with ADT. (Source: CancerNetwork)
Source: CancerNetwork - June 10, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

First-Line Treatment of Hormone-Sensitive Metastatic PCa First-Line Treatment of Hormone-Sensitive Metastatic PCa
In addition to standard ADT, which patients with hormone-sensitive metastatic prostate cancer should receive abiraterone, docetaxel, both, or neither?Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 8, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

ASCO: Overall Survival Up for African - American Men With mCRPC
Improved survival versus Caucasian men treated with docetaxel/prednisone, DP - containing regimen (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 7, 2018 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Urology, Conference News, Source Type: news

ASCO: Overall Survival Up for African-American Men With mCRPC
THURSDAY, June 7, 2018 -- Overall survival is increased for African-American men with metastatic castration resistant prostate cancer (mCRPC) versus Caucasian men treated with docetaxel/prednisone (DP) or a DP-containing regimen, according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 7, 2018 Category: Pharmaceuticals Source Type: news

Targeting chemotherapy with genetic testing benefits women with aggressive breast cancer
(Institute of Cancer Research) Women with an aggressive form of breast cancer who have faults in their BRCA genes do much better on chemotherapy drug carboplatin than standard treatment, a major clinical trial reports. Researchers found that women with advanced 'triple-negative' breast cancer who had inherited a BRCA mutation were twice as likely to benefit from carboplatin as docetaxel, which is currently standard of care for these patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 30, 2018 Category: Cancer & Oncology Source Type: news

Novel TKI Plus Chemo Dramatically Shrank Advanced Head & amp; Neck Tumors
AZD1775, a small-molecule, WEE1-targeting TKI, significantly shrunk tumors when administered in combination with cisplatin and docetaxel in a phase I trial. (Source: CancerNetwork)
Source: CancerNetwork - April 25, 2018 Category: Cancer & Oncology Authors: Anne Landry Tags: Head & Neck Cancer Head and Neck Cancer Targets News Source Type: news

ASCO Issues New Metastatic Prostate Cancer Treatment Guide ASCO Issues New Metastatic Prostate Cancer Treatment Guide
Adding docetaxel or abiraterone to ADT improves metastatic prostate cancer survival, with patient and cost factors the most important considerations when choosing between them, say guidelines.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 18, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

MHSPC: Increased Survival with Added Docetaxel Confirmed Long-Term (CME/CE)
(MedPage Today) -- 13-month advantage in median overall survival (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 16, 2018 Category: Hematology Source Type: news

ASCO Supports New Options for Metastatic Prostate Cancer
(MedPage Today) -- Docetaxel, abiraterone plus ADT for non-CRPC (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - April 2, 2018 Category: Primary Care Source Type: news

Abiraterone, Docetaxel Best With ADT for Metastatic Prostate Cancer
Abiraterone plus prednisolone/prednisone, or docetaxel, combined with ADT may be the most effective therapies for metastatic hormone-naive prostate cancer. (Source: CancerNetwork)
Source: CancerNetwork - March 19, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Genitourinary Cancers News Prostate Cancer Source Type: news

NanOlogy looks to transform chemotherapy with localized delivery platform
Paclitaxel revolutionized cancer treatment when it was first used as a chemotherapeutic in the 1990s. But although the product is a powerful cancer killer, patients taking systemic doses of paclitaxel have to endure side effects such as peripheral neuropathy and hair loss. Marc Iacobucci and his team at NanOlogy believe they could replace the need for large, systemic doses of paclitaxel with the company’s unique formulation technique. NanOlogy has developed a way to turn drugs such as paclitaxel and docetaxel into sub-micron particles of pure drug that can be delivered locally to tumors. Get the full story ...
Source: Mass Device - March 5, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Oncology Pharmaceuticals nanology Source Type: news